Clinical Research Directory

Inclusion Criteria: * Patients suffering from POEMS syndrome (Mayo Clinic criteria) * Patients with a localised disease who can be treated with radiation and those with a disseminated disease and who can be treated intensively will be included in Group 1, all other patients will be included in Group 2. * Patients aged of 18 or more * Patients who do not show uncontrolled thrombosis * Patients who have been duly informed and who have signed a consent form. * Patients must respect all the lenalidomide Pregnancy Prevention Program (PPP) requirements described in appendix of the protocol. * Patients registered with the French National Health System. Exclusion Criteria: * Women who are pregnant, or suspected to be pregnant or breastfeeding * Pathology not linked with POEMS, contraindicating one of the studied drugs * Patients suffering from a deficiency which does not allow them full understanding of the trial requirements and which could compromise proper consent from the patient and/or observance of the protocol and continuous participation in the trial. * Prior history of malignancy other than POEMS syndrome or active other cancer or other serious illness. * Any contraindication to Revlimid® or to one of its excipient. * Patient with clearance creatinine \< 30mL/min. * Hepatic insufficiency * Patient with Absolute Neutrophil count (ANC) \< 1,0 x 109/L * Patient with platelet count \< 75 x 109/L * Use of any other experimental drug or therapy within 28 days of baseline * Known hypersensitivity to thalidomide * Instable, clinically significant ECG findings * Known positive for HIV, or active infectious hepatitis, type A, B or C * Patients under protection of a legal order.